Abstract Details

Title Association of Co-morbidities with Functional Outcomes in Stroke Patients with Atrial Fibrillation on long-term Oral anticoagulation

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P11 - Poster Session 11 (11:45 AM-12:45 PM)

Poster/Presentation
Number 6-030

Objective To assess the effect of pertinent co-morbidities and imaging findings on functional outcomes in patients with Atrial fibrillation (AF) taking oral anticoagulation (OAC) therapy who developed acute ischemic stroke (AIS).

Background Per current guidelines, most patients with AF are treated with OACs. However, these patients can still develop AIS. Exploring the underlying factors associated with worse functional outcomes is crucial.

Design/Methods We retrospectively reviewed 33 adult patients with AF on long-term OACs presenting with AIS. Information collected included demographic variables, medical history, and pertinent clinical and imaging parameters. A series of logistic regression models adjusted for age, gender, hypertension, diabetes, hyperlipidemia, and LVO were run to analyze the association of these parameters with AIS outcomes, assessed as binarized modified Rankin scale score (mRSS) (4-6: worse outcome vs 0-3: better outcome [ref]) and binarized NIH stroke scale (NIHSS) (>15: worse outcome vs 0-15: better outcome [ref]) at discharge. All analyses were conducted using SAS Studio OnDemand for Academics (SAS Institute Inc., Cary, NC).

Results Among 33 patients (mean age 74 + 13.6 years, 51.5% males) assessed for binarized mRSS, presence of LVO showed 21.1 times the odds of a poor outcome (OR: 21.1, 95% CI: 1.68, 265.27, p=0.02). When assessed for NIHSS at discharge, presence of LVO showed 3.82 times the odds of a poor outcome (OR: 3.82, 95% CI: 0.37, 39.03, p=0.26). When assessed for binarized mRSS outcome, hyperlipidemia showed 9.87 times the odds of a poor outcome (OR: 9.87, 95% CI: 0.9, 108.13, p=0.06). When assessed for binarized NIHSS at discharge, hyperlipidemia showed 18.4 times the odds of a poor outcome (OR: 18.4, 95% CI: 1.3, 261.28, p=0.03).

Conclusions Our analysis revealed significant associations between the presence of LVO and worse mRSS at discharge and between HLD and worse NIHSS at discharge. However, further research is needed by employing matched controls.

Authors/Disclosures
Mohammad A. Sheikh, MBBS (LSU Health Shreveport) PRESENTER	Dr. Sheikh has nothing to disclose.
Muhammad Ayub, MD (Louisiana State University, Shreveport)	Dr. Ayub has nothing to disclose.
Junaid Ansari, MD (LSU Health Shreveport)	Dr. Ansari has nothing to disclose.
Omar Elsekaily, MBBS (LSU shreveport)	Dr. Elsekaily has nothing to disclose.
Prabandh R. Buchhanolla, MBBS	Dr. Buchhanolla has nothing to disclose.
Amir Neshatfar, MD (Cox health hospital)	Dr. Neshatfar has nothing to disclose.
Maithreyi Chappidi, MD (Univrsity of Alabama Birmingham)	Dr. Chappidi has nothing to disclose.
Arvin Parvathaneni, MD (LSU Health Shreveport)	Dr. Parvathaneni has nothing to disclose.
Rachel E. Glasser, MD (Case Western / University Hospitals Cleveland)	Dr. Triay has nothing to disclose.
	No disclosure on file
	No disclosure on file
Hugo Cuellar-Saenz	No disclosure on file
Roger E. Kelley, Jr., MD, FAAN (LSU Health Sciences Center)	Dr. Kelley has nothing to disclose.
Vijayakumar Javalkar, MD, MCh, FAAN (LSUHSC Shreveport)	Dr. Javalkar has nothing to disclose.

��ɫ��

��ɫ��